US20160309768A1 - Synthetic milk compositions for optimal growth and development and prevention of obesity in male and female infant and children - Google Patents
Synthetic milk compositions for optimal growth and development and prevention of obesity in male and female infant and children Download PDFInfo
- Publication number
- US20160309768A1 US20160309768A1 US15/104,027 US201415104027A US2016309768A1 US 20160309768 A1 US20160309768 A1 US 20160309768A1 US 201415104027 A US201415104027 A US 201415104027A US 2016309768 A1 US2016309768 A1 US 2016309768A1
- Authority
- US
- United States
- Prior art keywords
- composition
- infant
- kcal
- infants
- energy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 166
- 230000012010 growth Effects 0.000 title claims abstract description 26
- 208000008589 Obesity Diseases 0.000 title claims abstract description 23
- 235000020824 obesity Nutrition 0.000 title claims abstract description 23
- 239000008267 milk Substances 0.000 title description 22
- 235000013336 milk Nutrition 0.000 title description 20
- 210000004080 milk Anatomy 0.000 title description 20
- 238000011161 development Methods 0.000 title description 5
- 230000002265 prevention Effects 0.000 title description 2
- 235000016709 nutrition Nutrition 0.000 claims abstract description 54
- 150000003904 phospholipids Chemical class 0.000 claims description 36
- 150000002632 lipids Chemical class 0.000 claims description 33
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 32
- 235000020256 human milk Nutrition 0.000 claims description 30
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 29
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 29
- 210000004251 human milk Anatomy 0.000 claims description 29
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 29
- 150000003905 phosphatidylinositols Chemical class 0.000 claims description 27
- 235000013350 formula milk Nutrition 0.000 claims description 26
- 235000006180 nutrition needs Nutrition 0.000 claims description 26
- 235000020778 linoleic acid Nutrition 0.000 claims description 21
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 21
- 239000002253 acid Substances 0.000 claims description 19
- 150000007513 acids Chemical class 0.000 claims description 19
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 235000020209 toddler milk formula Nutrition 0.000 abstract description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 239000002904 solvent Substances 0.000 description 16
- 229920001542 oligosaccharide Polymers 0.000 description 14
- 235000015097 nutrients Nutrition 0.000 description 13
- 239000006041 probiotic Substances 0.000 description 12
- 235000018291 probiotics Nutrition 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 10
- 150000002482 oligosaccharides Chemical class 0.000 description 10
- 150000002500 ions Chemical class 0.000 description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 8
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 235000005911 diet Nutrition 0.000 description 8
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 8
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 7
- 229960001231 choline Drugs 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 6
- 230000000529 probiotic effect Effects 0.000 description 6
- 108010046377 Whey Proteins Proteins 0.000 description 5
- 102000007544 Whey Proteins Human genes 0.000 description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 description 5
- 229960004488 linolenic acid Drugs 0.000 description 5
- 239000011707 mineral Substances 0.000 description 5
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 description 5
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
- 235000013406 prebiotics Nutrition 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 4
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 4
- 241001608472 Bifidobacterium longum Species 0.000 description 4
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 4
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 description 4
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 4
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 4
- 229930003451 Vitamin B1 Natural products 0.000 description 4
- 229930003779 Vitamin B12 Natural products 0.000 description 4
- 229930003471 Vitamin B2 Natural products 0.000 description 4
- 229930003268 Vitamin C Natural products 0.000 description 4
- 229930003316 Vitamin D Natural products 0.000 description 4
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 4
- 229930003427 Vitamin E Natural products 0.000 description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
- 229940009289 bifidobacterium lactis Drugs 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 239000005018 casein Substances 0.000 description 4
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 4
- 235000021240 caseins Nutrition 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 235000004626 essential fatty acids Nutrition 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 235000019387 fatty acid methyl ester Nutrition 0.000 description 4
- 229960000304 folic acid Drugs 0.000 description 4
- 235000019152 folic acid Nutrition 0.000 description 4
- 239000011724 folic acid Substances 0.000 description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 4
- 230000000774 hypoallergenic effect Effects 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000012263 liquid product Substances 0.000 description 4
- 229960003512 nicotinic acid Drugs 0.000 description 4
- 235000001968 nicotinic acid Nutrition 0.000 description 4
- 239000011664 nicotinic acid Substances 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 229940055726 pantothenic acid Drugs 0.000 description 4
- 235000019161 pantothenic acid Nutrition 0.000 description 4
- 239000011713 pantothenic acid Substances 0.000 description 4
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 4
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 4
- 235000019175 phylloquinone Nutrition 0.000 description 4
- 239000011772 phylloquinone Substances 0.000 description 4
- 229960001898 phytomenadione Drugs 0.000 description 4
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 4
- 229960002477 riboflavin Drugs 0.000 description 4
- 229960003495 thiamine Drugs 0.000 description 4
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 4
- 235000019155 vitamin A Nutrition 0.000 description 4
- 239000011719 vitamin A Substances 0.000 description 4
- 235000010374 vitamin B1 Nutrition 0.000 description 4
- 239000011691 vitamin B1 Substances 0.000 description 4
- 235000019163 vitamin B12 Nutrition 0.000 description 4
- 239000011715 vitamin B12 Substances 0.000 description 4
- 235000019164 vitamin B2 Nutrition 0.000 description 4
- 239000011716 vitamin B2 Substances 0.000 description 4
- 235000019158 vitamin B6 Nutrition 0.000 description 4
- 239000011726 vitamin B6 Substances 0.000 description 4
- 235000019154 vitamin C Nutrition 0.000 description 4
- 239000011718 vitamin C Substances 0.000 description 4
- 235000019166 vitamin D Nutrition 0.000 description 4
- 239000011710 vitamin D Substances 0.000 description 4
- 150000003710 vitamin D derivatives Chemical class 0.000 description 4
- 235000019165 vitamin E Nutrition 0.000 description 4
- 239000011709 vitamin E Substances 0.000 description 4
- 229940046009 vitamin E Drugs 0.000 description 4
- 229940045997 vitamin a Drugs 0.000 description 4
- 229940011671 vitamin b6 Drugs 0.000 description 4
- 229940046008 vitamin d Drugs 0.000 description 4
- 235000021119 whey protein Nutrition 0.000 description 4
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 3
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 229940009291 bifidobacterium longum Drugs 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 235000020247 cow milk Nutrition 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 235000020218 follow-on milk formula Nutrition 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000007407 health benefit Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 235000021073 macronutrients Nutrition 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- FVVCFHXLWDDRHG-UPLOTWCNSA-N (2s,3r,4s,5r,6r)-2-[(2r,3s,4r,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O1 FVVCFHXLWDDRHG-UPLOTWCNSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- 208000016444 Benign adult familial myoclonic epilepsy Diseases 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 241000186012 Bifidobacterium breve Species 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 241000194031 Enterococcus faecium Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000186605 Lactobacillus paracasei Species 0.000 description 2
- 241000917009 Lactobacillus rhamnosus GG Species 0.000 description 2
- 241000186869 Lactobacillus salivarius Species 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- 241000906086 Miris Species 0.000 description 2
- 206010033307 Overweight Diseases 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 235000021196 dietary intervention Nutrition 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 208000016427 familial adult myoclonic epilepsy Diseases 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- ZGNITFSDLCMLGI-UHFFFAOYSA-N flubendiamide Chemical compound CC1=CC(C(F)(C(F)(F)F)C(F)(F)F)=CC=C1NC(=O)C1=CC=CC(I)=C1C(=O)NC(C)(C)CS(C)(=O)=O ZGNITFSDLCMLGI-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 2
- 150000003271 galactooligosaccharides Chemical class 0.000 description 2
- 150000002270 gangliosides Chemical class 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 235000021125 infant nutrition Nutrition 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940059406 lactobacillus rhamnosus gg Drugs 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000003050 macronutrient Effects 0.000 description 2
- 150000003272 mannan oligosaccharides Chemical class 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- -1 phosphatidylcholine Chemical class 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000013179 statistical model Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 1
- 241001134770 Bifidobacterium animalis Species 0.000 description 1
- 241001213452 Bifidobacterium longum NCC2705 Species 0.000 description 1
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 102400000739 Corticotropin Human genes 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 238000001134 F-test Methods 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000005905 Hydrolysed protein Substances 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 241000235649 Kluyveromyces Species 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical group C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 241001147746 Lactobacillus delbrueckii subsp. lactis Species 0.000 description 1
- 241001468157 Lactobacillus johnsonii Species 0.000 description 1
- 241001406038 Lactobacillus johnsonii NCC 533 Species 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
- 241000194036 Lactococcus Species 0.000 description 1
- 102100037611 Lysophospholipase Human genes 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- SQVRNKJHWKZAKO-LUWBGTNYSA-N N-acetylneuraminic acid Chemical group CC(=O)N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-LUWBGTNYSA-N 0.000 description 1
- 208000007683 Pediatric Obesity Diseases 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 244000057717 Streptococcus lactis Species 0.000 description 1
- 235000014897 Streptococcus lactis Nutrition 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 235000021407 appetite control Nutrition 0.000 description 1
- 235000021229 appetite regulation Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000004251 balanced diet Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940118852 bifidobacterium animalis Drugs 0.000 description 1
- 229940004120 bifidobacterium infantis Drugs 0.000 description 1
- 235000020246 buffalo milk Nutrition 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 230000031154 cholesterol homeostasis Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000000119 electrospray ionisation mass spectrum Methods 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 238000000105 evaporative light scattering detection Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 239000005350 fused silica glass Substances 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000020251 goat milk Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 235000021129 infant diet Nutrition 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 229940072205 lactobacillus plantarum Drugs 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- 238000010234 longitudinal analysis Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000008111 motor development Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 235000021140 nondigestible carbohydrates Nutrition 0.000 description 1
- 238000004305 normal phase HPLC Methods 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 1
- 229940033080 omega-6 fatty acid Drugs 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000009862 primary prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960002181 saccharomyces boulardii Drugs 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002235 transmission spectroscopy Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
Definitions
- the invention concerns synthetic nutritional compositions for infants and young children up to the age of thirty-six months, particularly infant formulae and growing-up milks.
- the compositions vary according to sex of the infant or young child.
- human breast milk represents the uncontested gold standard in terms of infant nutrition.
- breastfeeding is inadequate or unsuccessful for medical reasons or because of mother choice not to breastfeed.
- Infant formulae have been developed for these situations.
- Infant formulae, follow-up formulae and grown-up milks which may be aimed at different age groups of 0 to 6 months, 6 months to 1 year and 1 year to 3 years respectively, are known. These infant formulae, follow-up formulae and growing-up milks aim to meet the requirements of infants and young children at the different ages.
- An age-tailored nutrition system for infants is described in WO 2009/068549, wherein a protein nature and content are adapted to specific age groups.
- the recommended World Health Organization (WHO) and Codex Alimentarius Commission guidelines for infant formulae and follow-up formulae state that the infant formulae and follow-up formulae shall not provide less than 60 kcal/100 mL and not more than 85 kcal/100 mL.
- breast milk may contribute to the protective effects of breastfeeding against obesity in infants later in life [Ian M. P., et al. (2009) Opportunities for the Primary Prevention of Obesity during Infancy, Adv Pediatr. 56:107-133; Tounian P., (2011) Programming towards Childhood Obesity, Ann. Nutr. Metab. 58:30-41].
- infant formulae and/or follow-up formulae dosage and caloric density do not take into consideration the complementary food eaten by infants and young children when overfeeding the infants and young children.
- starter formulas that target all children of 0-6 months do not distinguish the nutritional needs of infants aged 0-3 months from those aged 3 to 6 months old. It is known that breast milk composition changes considerably from the first to second and third month of lactation for example.
- infant formulae and/or follow-up formulae do not take into consideration the sex of the child.
- Powe and associates [Powe C. E. et al. (2010); Infant sex predicts breast milk energy content, American journal of human biology, 22:50-54] have recently reported differences in energy content based on the gender of the new born infant. Milk secreted from the mothers of male infant was reported to be 25% greater in energy content when compared with the milk of mothers of female infants. This recent data is not surprising given that girls and boys have different physiological needs based upon the World Health Organization standard growth curves for boys and girls. Thus, the tendency to overfeed infants and young children is even more accentuated for girls, because the composition of current infant formulae and/or follow-up formulae of known infant formulae is the same for boys and girls.
- This diet should take into account the gender of the infant or young child. It should also take into account the age of the child, specifically in months, for example 0-3, 3-6, 6-12 months etc. The diet should promote health benefits in the long term to the infants and young children.
- the inventors have analyzed the milk from mothers to boys and from mothers to girls, at 30, 60 and 120 days post-partum in a longitudinal clinical study. Based on their results, they have designed synthetic nutritional formulas that have distinct amounts of certain nutrients for boys and for girls.
- the compositions of the present invention have been designed to ensure balanced growth and to prevent obesity in infancy and later in life.
- the present invention concerns synthetic nutritional formulations for infants and young children, meaning in the context of the invention, up to the age of 36 months.
- the compositions are especially adapted to the gender and the age of the child.
- the invention further relates to administration of these compositions for promoting balanced growth and preventing obesity.
- the first aspect of the invention concerns a synthetic nutritional composition especially adapted to the nutritional needs of a male infant or child.
- the composition comprises:
- composition may also comprise:
- composition may also comprise one or a mixture of phopholipids e.-g.:
- composition additionally comprises:
- composition is especially adapted to the nutritional needs of a male infant less than 3 months old.
- This composition comprises:
- composition is especially adapted to the nutritional needs a male infant or child older than 3 months old and younger than 36 months.
- This composition comprises:
- a synthetic nutritional composition especially adapted to the nutritional needs of a female infant or young child comprising:
- the synthetic nutritional composition also comprises:
- the synthetic nutritional composition also comprises any one or a mixture of phospholipids e.-g.:
- the synthetic nutritional composition also comprises:
- composition is especially adapted to the nutritional needs of a female infant younger than 3 months old.
- This composition comprises:
- composition for females is especially adapted to the nutritional needs of a female infant or child older than 3 months old and younger than 36 months.
- This composition is according to the second aspect of the invention, and comprises:
- a set of two distinct synthetic nutritional compositions wherein the first composition is especially adapted to the nutritional needs of a male infant or child, as described according to the first aspect of the invention.
- the second composition as described according to the first aspect of the invention is especially adapted to the nutritional needs of a female infant or child.
- the compositions of the invention are designed to ensure balanced growth and prevent obesity in male and female infants or young children during infancy, childhood and later in life.
- the synthetic nutritional composition of the invention may be an infant formula in the form of a powder, liquid or concentrated liquid, or is a human milk fortifier.
- FIGS. 1-3 show the results of the analysis of nutrients in the breast milk of 50 mothers in trial detailed in Example 1. Samples were taken at 30, 60 and 120 days post-partum. Quantities were measured in mg/100 ml. The measurements of milk of mothers to boys are shown with a dashed line, while the solid line shows the measurements of milk of mothers to girls.
- the P[gender] value relates to the differences in milk with respect to the sex of the baby.
- the P[age] values are differences in gender with respect to time; P[age] is a P value considering a linear model and P[age 2 ] using a quadratic model.
- FIG. 1A shows energy density
- FIG. 1B lipids
- FIG. 1C linoleic acid
- FIG. 3A shows phosphatidylcholine
- FIG. 3B shows phosphatidylethanolamine
- FIG. 3C shows phosphatidylinositol
- FIG. 3D shows total phospholipids.
- infants according to the Commission Directive 2006/141/EC of 22 Dec. 2006 on infant formulae and follow-on formulae, article 1.2 (a), the term “infants” means children under the age of 12 months.
- Young Children (including young boys and young girls): according to the Commission Directives 2006/141/EC of 22 Dec. 2006 and/or 91/321/EEC of 14 May 1991 on infant formulae and follow-on formulae, article 1.2 (b), the term “young children” means children aged between one and three years.
- infant formulae according to the Commission Directives 2006/141/EC of 22 Dec. 2006 and/or 91/321/EEC of 14 May 1991 on infant formulae and follow-on formulae, article 1.2 (c), the term “infant formulae” means foodstuffs intended for particular nutritional use by infants during the first four to six months of life and satisfying by themselves the nutritional requirements of this category of persons. It has to be understood that infants can be fed solely with infant formulas, or that the infant formula can be used by the carer as a complement of human milk. It is synonymous to the widely used expression “starter formula”.
- follow-on formulae according to the Commission Directives 2006/141/EC of 22 Dec. 2006 and/or 91/321/EEC of 14 May 1991 on infant formulae and follow-on formulae, article 1.2 (d), the term “follow-on formulae” means foodstuffs intended for particular nutritional use by infants aged over four months and constituting the principal liquid element in a progressively diversified diet of this category of persons.
- Growing-up milk milk-based nutritional composition especially adapted to a child of between one year and three years old.
- Human Milk fortifier Nutritional composition for infants or young children intended to be added to or diluted with human milk.
- hypoallergenic composition means a composition which is unlikely to cause allergic reactions.
- sialylated oligosaccharide means an oligosaccharide having a sialic acid residue.
- fucose residue means an oligosaccharide having a fucose residue.
- prebiotic means non-digestible carbohydrates that beneficially affect the host by selectively stimulating the growth and/or the activity of healthy bacteria such as bifidobacteria in the colon of humans [Gibson G R, Roberfroid M B. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics . J Nutr. 1995; 125:1401-12].
- probiotic means microbial cell preparations or components of microbial cells with a beneficial effect on the health or well-being of the host [Salminen S, Ouwehand A. Benno Y. et al. “ Probiotics: how should they be defined ” Trends Food Sci. Technol. 1999:10 107-10].
- An “allergy” is an allergy which has been detected by a medical doctor and which can be treated occasionally or in a more durable manner.
- a “food allergy” is an allergy with respect to a nutritional composition.
- the present inventors have carried out a major study on breast milk composition. This study involved both developing advanced analytical technologies to analyze milk samples and performing a longitudinal clinical trial with human milk sampling at 30, 60 and 120 days post-partum (see Example 1).
- the milk samples were quantitatively analyzed for macronutrients, fatty acids and phospholipids.
- the inventors have surprisingly found very significant differences, between milk of mothers of male infants compared to that of female infants, not only in energy (differences are greater than previously reported), but also in the quantities of lipids, total polyunsaturated acids (PUFAs) and phospholipids.
- PUFAs total polyunsaturated acids
- results of this trial indicated surprisingly significant differences in the levels of linoleic acid (LA), phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, phosphatidylserine and total phospholipids for boys and girls (see Table 2 and FIGS. 1-3 ). In some cases, this difference between male and female destined milk varied over time (between 0-120 days).
- LA linoleic acid
- phosphatidylcholine phosphatidylethanolamine
- phosphatidylinositol phosphatidylserine
- total phospholipids for boys and girls
- compositions that are especially adapted to meet the nutritional needs of male and female infant and young children.
- no gender specific formulations for infants or young children are known.
- compositions According to the Invention:
- compositions of the invention are designed to meet the nutritional needs of male and female infants and young children.
- the compositions ensure balanced growth and prevent obesity in male and female infants or young children and later in life.
- the synthetic nutritional compositions of the invention are designed for consumption by children from birth to three years old. They are specifically designed to be gender specific. In certain embodiments, they are also age specific, being designed for infants younger than three months old, or older than three months, but less than 36 months.
- the synthetic nutritional compositions of the invention may be an infant formula in the form of a powder, liquid or concentrated liquid.
- the infant formula may be based on a cow's milk, goat's milk or buffalo milk.
- the infant formula may be a starter formula for infants that are less than 6 months old or a follow-on formula for infants that are more than 6 months old.
- the composition of the invention may be a growing up milk, or a human milk fortifier.
- the composition may be cow's milk whey based infant formula.
- the formula may also be a hypoallergenic (HA) formula in which the cow milk proteins are (partially or extensively) hydrolysed.
- the formula may also be based on soy milk or a non-allergenic formula, for example one based on free amino acids.
- the nutritional compositions of the invention contain specific quantities of lipids, essential fatty acids, specifically linoleic acid (LA), and polyunsaturated fatty acids (PUFAs).
- the specific quantities of these nutrients are gender specific.
- Quantities of phospholipids including phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol and phosphatidylserine also vary for male and female destined compositions.
- the total number of phospholipids also varies. All of the latter components—essential fatty acids, sphingomyelin and phospholipids, are known to be important for balanced growth.
- the quantities of all the nutrients expressed herein as mg/100 ml or g/100 ml reflect the amounts of nutrients present in the final liquid product, to be consumed by the infant or young child.
- the composition may be a powdered infant formula that is diluted with water to give a final liquid product.
- the composition according to the invention may also be a concentrated liquid that is diluted with water to achieve the final liquid product.
- the composition of the invention may be a liquid product that is directly consumed by the infant or child as is.
- the composition according to the invention may be a human milk fortifier that is added to or diluted with human milk. In this case, the concentration of the nutrients already present in the human milk (to which the human milk fortifier is added) are to be taken as the average values for lactating mothers that are known or predicted from published clinical data.
- the first aspect of the invention concerns a synthetic nutritional composition especially adapted to the nutritional needs of a male infant or child.
- the composition comprises:
- composition may also comprise:
- composition may also comprise one or a mixture of phopholipids e.-g.:
- composition additionally comprises:
- composition is especially adapted to the nutritional needs of a male infant less than 3 months old.
- This composition comprises:
- composition is especially adapted to the nutritional needs a male infant or child older than 3 months old and younger than 36 months.
- This composition comprises:
- a synthetic nutritional composition especially adapted to the nutritional needs of a female infant or young girl comprising:
- the synthetic nutritional composition also comprises any one or a mixture of phospholipids e.-g.:
- the synthetic nutritional composition also comprises:
- composition is especially adapted to the nutritional needs of a female infant younger than 3 months old.
- This composition comprises:
- composition for females is especially adapted to the nutritional needs of a female infant or child older than 3 months old and younger than 36 months.
- This composition is according to the second aspect of the invention, and comprises:
- a set of two distinct synthetic nutritional compositions comprising a first composition and second composition.
- the first composition is any of the compositions described above that are especially adapted to the nutritional needs of a male infant or child.
- the second composition is any of the compositions described above that is especially adapted to the nutritional needs of a female infant or child.
- the first and second compositions are conditioned separately.
- the first and second compositions in the set are commercialized under the same marketing concept umbrella.
- the set of the invention can preferably be commercialized under the same marketing concept (for example gender segmentation and/or specific adaptation of nutritional compositions for male and female infants or children).
- the first and second compositions are distinct in that they differ by at least 10% in the quantity of at least one of the common components in the two compositions chosen among a. to h.
- the first and second compositions may be then conditioned separately, or group together in another outer container, or packaging.
- the packaging may be for example simply a layer or plastic film, a bag, box, piece of foil, or other means to keep the first and second compositions grouped together.
- the set may comprise additional third, fourth and fifth etc. compositions that are especially adapted to meet the nutritional needs of infants or young children that are for example, 3-6 months old 6-9 months old or 9-12 months old.
- the set may also contain additional compositions that target in the same way children older than one year up to three years old.
- compositions of the invention may also be present in the compositions of the invention.
- the nutritional compositions of the invention may contain other ingredients which may act to enforce the technical effect of the components a.-k.
- the prebiotics that may be used in accordance with the present invention are not particularly limited and include all food substances that promote the growth of probiotics or health beneficial micro-organisms in the intestines.
- they may be selected from the group consisting of oligosaccharides, optionally containing fructose, galactose, mannose; dietary fibers, in particular soluble fibers, soy fibers; inulin; or mixtures thereof.
- Preferred prebiotics are fructo-oligosaccharides (FOS), galacto-oligosaccharides (GOS), isomalto-oligosaccharides (IMO), xylo-oligosaccharides (XOS), arabino-xylo oligosaccharides (AXOS), mannan-oligosaccharides (MOS), oligosaccharides of soy, glycosylsucrose (GS), lactosucrose (LS), lactulose (LA), palatinose-oligosaccharides (PAO), malto-oligosaccharides, gums and/or hydrolysates thereof, pectins and/or hydrolysates thereof.
- FOS fructo-oligosaccharides
- GOS galacto-oligosaccharides
- IMO isomalto-oligosaccharides
- XOS xylo-oligosaccharides
- AXOS arabino-xy
- the human milk oligosaccharides for example sialylated oligosaccharides, described in WO 2012/069416 published on May 31, 2012 may be included in the composition according to the invention.
- the latter oligosaccharides may act in synergy with the essential fatty acids and phospholipids of the invention to promote the healthy establishment of cognitive function in the young developing infant or young child.
- Probiotic may be added to the composition. All probiotic micro-organisms may be added additionally.
- the probiotic may be selected for this purpose from the group consisting of Bifidobacterium, Lactobacillus, Lactococcus, Enterococcus, Streptococcus, Kluyveromyces, Saccharoymces, Candida , in particular selected from the group consisting of Bifidobacterium longum, Bifidobacterium lactis, Bifidobacterium animalis, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium adolescentis, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus paracasei, Lactobacillus salivarius, Lactobacillus lactis, Lactobacillus rhamnosus, Lactobacillus johnsonii, Lactobacillus plantarum, Lactobacillus salivarius, Lactococcus lac
- the synthetic nutritional compositions of the invention comprise probiotics active or inactivated, dead or alive, preferably in sufficient dose to be effective (e.g between 10 6 to 10 11 or between 10 7 and 10 9 cfu/g of composition).
- the composition of the invention for male infant comprises a probiotic having a specific effect for male infant and is different from the probiotic comprised in the composition of the invention for female infant.
- such probiotics comprise Bifidobacterium lactis or Lactobacillus rhamnosus GG for male and B. Longum for female (or possibly vice-versa).
- probiotics comprise Bifidobacterium Lactis for male and Lactobacillus Rhamnosus for female (or possibly vice-versa).
- the choice of probiotics is specifically adapted for the particular needs of male and female infants, in particular for the optimum growth and/or prevention of obesity later in life.
- Vitamins, minerals and other micronutrients suitable for administration to children under the age of three may be added to the compositions of the invention.
- compositions of the Invention Promote the Balanced Development and Prevent Obesity Later in Life:
- compositions according to the invention are especially adapted to promote the balanced growth and prevent obesity in infants and young children.
- the indicators of normative growth are defined by World Health Organization (WHO) [Acta P ⁇ diatrica, 2006; Suppl 450: 76-85]. These indicators are: length/height-for-age, weight-for-age weight-for-length, weight-for-height, body mass, index-for-age (BMI-for-age), head circumference-for-age, arm circumference-for-age, subscapular skinfold-for-age, triceps skinfold-for-age, motor development milestones, weight velocity, length velocity and head circumference velocity. Furthermore, each indicator is available independently for male and female gender of the infant. The value of any particular indicator of an infant between 3rd and 97th percentile at a corresponding time point is considered normal and/or optimal.
- Lipids in human milk provide to the infant the calories needed for growth as well as essential fatty acids and phospholipids such as phosphatidylcholine, phosphatidyethanolamine, phosphatidylserine, phosphatidylinositol and spingomelin [Jensen R G., (1999), Lipids in Human Milk, Lipids 34, 1243-1271].
- the essential fatty acids include alpha-linolenic acid (ALA), an omega-3 fatty acid, and linoleic acid (LA), an omega-6 fatty acid. ALA and LA cannot be synthesized by humans and thus must be obtained from the diet.
- PC Phosphatidylcholine
- choline are critically important nutrients for the normal development of the infant [Zeisel, S. H. (1998) Choline and Phosphatidylcholine are important components of an infant's diet, in Lipids in Infant Nutrition, AOCS Press, Champaign, Ill.].
- Phosphatidylcholine is the prevalent phospholipid found in cell membranes and is an important methyl donor and is involved in cholesterol homeostasis. Metabolism of PC, sphingomyelin and phosphatidylethanolamine (PE) are related, and therefore, PE is an important nutrient to support infant growth and development.
- dietary phospholipids such as PC, PE and phosphatidylinositol are converted into lyphosphospholipids in the gastrointestinal tract by the action of the phospholipase A2 [Chanussot F., Lécithine, metabolism et nutrition, Lavoisier (2008)].
- compositions according to the invention that are especially adapted to meet the nutritional needs of male infants and young children promote balanced growth in these male infants and young children and prevent obesity these children later in life.
- compositions according to the invention that are especially adapted to meet the nutritional needs of female infants and young children promote balanced growth in these female infants and young children and prevent obesity these children later in life.
- the synthetic nutritional composition of the invention is an infant formula (or a follow-on formula or a growing up milk or a human milk fortifier), for infant of less than 36 months, less than 24 months, less than 12 months, less than 6 months or preferably of 3 months or less. It is generally known, or at least hypothesized, that early nutritional interventions can be more effective (in comparison to intervention at later stages in life) in programming the metabolic pathways of the infants to induce optimal balanced growth and thus prevent obesity during infancy and later in life
- the synthetic nutritional composition of the invention is an infant formula intended and/or especially designed for preterm infants and/or caesarean-born infants. It is generally known, or at least hypothesized, that these subject groups are more prone to suffer from unbalanced growth (and, thus, from being obese later in life) due to the immaturity of their metabolic pathways and physiological conditions at birth. Early adaptation and control of the diet is therefore of the highest importance.
- the synthetic nutritional composition of the invention is an infant formula (or a follow-on formula or a growing up milk or a human milk fortifier), for infants born from mothers or parents having a history of obesity or overweight. It is generally known, or at least hypothesized, that these subjects groups are more prone to suffer from unbalanced growth (and, thus, from being obese later in life), due, for example, to genetic or epi-genetic predispositions. It is, therefore, critical to address such issues as early as possible during infancy by a specifically adapted diet.
- the present inventors designed a longitudinal clinical trial with 50 lactating mothers with milk sampling at 30 (visit 1), 60 (visit 2) and 120 (visit 3) days post-partum.
- the milk samples were quantitatively analyzed for energy and total solids.
- the MIR analyses were performed with the Human Milk Analyzer (HMA, Miris, Sweden).
- the HMA is based on a semisolid MIR transmission spectroscopy, designed specifically for determination of the macronutrient composition of human milk.
- the use of the machine was according to manufacturer's instructions. Briefly 1 mL of previously warmed sample (up to 40° C. in water bath) was sonicated for 1 min before manual injection to the milk inlet. The analysis was conducted within next minute before the milk was retrieved and the inlet washed with de-ionized water. The cell was also washed with supplied detergent every 5 sample injections. Also every 10 samples an in-house control as well as calibrating standard provided by Miris were ran for quality control purposes.
- Fatty acid methyl esters were prepared using HCl/Methanol (3N) as a catalyst.
- the methylation procedure was as follows: In a 15 mL test tube equipped with Teflon-lined screw caps, 250 ⁇ L of human milk was added followed by 300 ⁇ L of internal standard FAME 11:0 and 300 ⁇ L of internal standard TAG 13:0, 2 mL of methanol, 2 mL of methanol/HCL (3N) and 1 mL of n-hexane. Test tubes were firmly capped, shaken vigorously and heated at 100° C. for 60 min, with occasional additional shaking. Care was taken to fit the cap tightly with cap liner to avoid leaks when tubes are heated at 100° C.
- a 7890A gas-chromatograph with a 7693 autosampler with preparative station module (Agilent Technologies, Palo Alto, Calif.) equipped with a fused-silica CP-Sil 88 capillary column (100% cyanopropylpolysiloxane; 100 m, 0.25 mm id, 0.25 ⁇ m film thickness; Agilent, Palo Alto, Calif.) was used with a split injector (1:25 ratio) heated at 250° C. and a flame-ionization detector operated at 300° C.
- the oven temperature programming used was 60° C. isothermal for 5 min, increased to 165° C. at 15° C./min, isothermal for 1 min at this temperature, and then increased to 195° C.
- Phospholipid families were separated by normal-phase high-performance liquid chromatography using 2 Nucleosil 50-5, 250 ⁇ 3 mm, 5 ⁇ (Macherey-Nagel, Easton, USA) equipped with pre-column Nucleosil 50-5, 8 ⁇ 3 mm, 5 ⁇ (Macherey-Nagel, Easton, USA).
- the chromatography system consisted of an Agilent 1200 module (Agilent Technologies, Basel, Switzerland) and an in-line PL-ELS 1000 evaporative light scattering detector (Polymer Laboratories, Shropshire England). All chromatography was performed at 55° C.
- Gangliosides were separated by LC using an Aquity BEH C18 column (1.7 ⁇ m; 150 ⁇ 2.1 mm i.d.; Waters).
- the chromatography system consisted of Infinity 1290 modules (Agilent Technologies, Basel, Switzerland) coupled to triple quadrupole mass spectrometer (Applied biosystems/MSD Sciex, 5500 Ontario, Canada). All chromatography was performed at 50° C.
- Solvent A composed of water/methanol/ammonium acetate (1 mM) (90/10/0.1 v/v/v) and solvent B of methanol/ammonium acetate (1 mM) (100/0.1 v/v).
- Disialogangliosides 3 (GD3) and monosialogangliosides 3 (GM3), were monitored by transitions of the precursor ions to the m/z 290 product ion listed in the Table 1.
- the ion m/z 290 corresponds to Neu5Ac fragments obtained from B type of cleavage according to (13). Data were collected and processed using Multiquant software 2.1 (Applied Biosystems, Sciex, Ontario, Canada). Quantification was performed by calibration curve.
- Stock solutions of GD3 and GM3 were prepared in methanol 70% (1 mg/mL) and further dilutions to volume with methanol 70% were performed to give 6 concentration levels covering a range from 7.5 to 22.5 ⁇ g/mL.
- Total area of GD3 and GM3 was calculated as the sums of peak areas of the transitions of the precursor ions to the m/z 290 product ion.
- Data collection points are 1, 2 and 4 months after infants' birth.
- Table 2 shows the Min, Mean, SD and Max for each unit of measurement
- Statistical models fitted to the raw data are shown in FIGS. 1-3 . Longitudinal analysis was carried out using linear mixed models. The figures also show the sequential effect of each of the terms age, age 2 , gender and age-gender interactions in this particular order in terms of the P-value for the corresponding F-test.
- the P[age] is a P value considering a linear model and P[age 2 ] corresponds to a quadratic one.
- the appropriate model is chosen according to whether the trajectory is linear (P[age]) or curved (P[age 2 ]).
- Random effects are subject specific terms to model the underlying correlation between repeat measures.
- the protein source is a conventional mix of whey protein and casein.
- the protein source is a conventional mix of whey protein and casein.
- the protein source is a conventional mix of whey protein and casein.
- the protein source is a conventional mix of whey protein and casein.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pediatric Medicine (AREA)
- Dairy Products (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13196795 | 2013-12-12 | ||
EP13196795.2 | 2013-12-12 | ||
PCT/EP2014/068487 WO2015086170A1 (en) | 2013-12-12 | 2014-09-01 | Synthetic milk compositions for optimal growth and development and prevention of obesity in male and female infant and children |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2014/068487 A-371-Of-International WO2015086170A1 (en) | 2013-12-12 | 2014-09-01 | Synthetic milk compositions for optimal growth and development and prevention of obesity in male and female infant and children |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/514,301 Division US11357252B2 (en) | 2013-12-12 | 2019-07-17 | Synthetic milk compositions for optimal growth and development and prevention of obesity in male and female infant and children |
Publications (1)
Publication Number | Publication Date |
---|---|
US20160309768A1 true US20160309768A1 (en) | 2016-10-27 |
Family
ID=49759128
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/104,027 Abandoned US20160309768A1 (en) | 2013-12-12 | 2014-09-01 | Synthetic milk compositions for optimal growth and development and prevention of obesity in male and female infant and children |
US16/514,301 Active US11357252B2 (en) | 2013-12-12 | 2019-07-17 | Synthetic milk compositions for optimal growth and development and prevention of obesity in male and female infant and children |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/514,301 Active US11357252B2 (en) | 2013-12-12 | 2019-07-17 | Synthetic milk compositions for optimal growth and development and prevention of obesity in male and female infant and children |
Country Status (10)
Country | Link |
---|---|
US (2) | US20160309768A1 (es) |
EP (1) | EP3079500B1 (es) |
CN (1) | CN105792677A (es) |
AU (3) | AU2014361224A1 (es) |
CL (1) | CL2016001454A1 (es) |
ES (1) | ES2743206T3 (es) |
MX (1) | MX2016007634A (es) |
PH (1) | PH12016500765A1 (es) |
RU (1) | RU2678418C1 (es) |
WO (1) | WO2015086170A1 (es) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019038159A1 (en) * | 2017-08-22 | 2019-02-28 | Nestec S.A. | SEX SPECIFIC SYNTHETIC NUTRIENT COMPOSITIONS AND NUTRIENT SYSTEMS COMPRISING SAME |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015154260A1 (en) * | 2014-04-09 | 2015-10-15 | Nestle (China) Ltd. | Gender specific synthetic nutritional compositions and nutritional systems comprising them. |
WO2015154259A1 (en) * | 2014-04-09 | 2015-10-15 | Nestle (China) Ltd. | Gender specific synthetic nutritional compositions and nutritional systems comprising them |
WO2015154254A1 (en) * | 2014-04-09 | 2015-10-15 | Nestle (China) Ltd. | Gender specific synthetic nutritional compositions and nutritional systems comprising them |
WO2015154257A1 (en) * | 2014-04-09 | 2015-10-15 | Nestle (China) Ltd. | Gender specific synthetic nutritional compositions and, nutritional systems comprising them |
WO2015154251A1 (en) * | 2014-04-09 | 2015-10-15 | Nestle (China) Ltd. | Gender specific synthetic nutritional compositions and nutritional systems comprising them. |
WO2015154263A1 (en) * | 2014-04-09 | 2015-10-15 | Nestle (China) Ltd. | Gender specific synthetic nutritional compositions and nutritional systems comprising them |
WO2015154256A1 (en) * | 2014-04-09 | 2015-10-15 | Nestle (China) Ltd. | Gender specific synthetic nutritional compositions and,nutritional systems comprising them |
WO2015154265A1 (en) * | 2014-04-09 | 2015-10-15 | Nestle (China) Ltd. | Gender specific synthetic nutritional compositions and nutritional systems comprising them |
US20200221751A1 (en) * | 2015-08-27 | 2020-07-16 | Nestec S.A. | Gender specific synthetic nutritional compositions and nutritional systems comprising them |
EP3648617A1 (en) * | 2017-07-07 | 2020-05-13 | Société des Produits Nestlé S.A. | Human milk fortifier |
WO2023208925A1 (en) | 2022-04-25 | 2023-11-02 | N.V. Nutricia | Nutritional composition for use in preventing programmed obesity in female infants |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080000333A1 (en) * | 2006-06-30 | 2008-01-03 | Nitto Seiko Co., Ltd. | Screw fastening machine |
US20120012175A1 (en) * | 2010-07-19 | 2012-01-19 | Samsung Electronics Co., Ltd. | Solar cell and manufacturing method thereof |
US20130017766A1 (en) * | 2011-07-12 | 2013-01-17 | Iv Technologies Co., Ltd. | Polishing pad, polishing method and polishing system |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4221291A (en) | 1978-06-20 | 1980-09-09 | General Foods Corporation | Container having separate storage facilities for two materials |
US4524078A (en) | 1982-01-04 | 1985-06-18 | General Foods Corporation | Pressurized container providing for the separate storage of a plurality of materials |
GB8928893D0 (en) | 1989-12-21 | 1990-02-28 | Whitbread & Co Plc | Carbonated beverage container |
ES2033193B1 (es) | 1990-10-30 | 1994-01-16 | Ganadera Union Ind Agro | Mezcla grasa para nutricion infantil y de adultos. |
US5601860A (en) | 1990-11-30 | 1997-02-11 | American Home Products Corporation | Corandomized fat compositions for infant formulas |
EP1062873A1 (en) | 1999-12-13 | 2000-12-27 | N.V. Nutricia | Improved infant formula, protein hydrolysate for use in such an infant formula, and method for producing such a hydrolysate |
US6495599B2 (en) * | 2000-04-13 | 2002-12-17 | Abbott Laboratories | Infant formulas containing long-chain polyunsaturated fatty acids and uses therof |
DE602004015169D1 (de) * | 2004-11-26 | 2008-08-28 | Nutricia Nv | Kleinkindernahrung mit proteasehemmer |
EP2382872A1 (en) | 2005-04-28 | 2011-11-02 | Enzymotec Ltd. | Polar lipid mixtures, their preparation and uses |
ES2350907T3 (es) * | 2005-07-01 | 2011-01-28 | N.V. Nutricia | Nutrición para bebés con proteínas hidrolizadas. |
AU2006327996B2 (en) | 2005-12-23 | 2012-03-29 | N.V. Nutricia | Infant nutritional compositions for preventing obesity |
US20080003330A1 (en) * | 2006-06-30 | 2008-01-03 | Ricardo Rueda | Infant formulas for early brain development |
US20080003329A1 (en) | 2006-06-30 | 2008-01-03 | Ricardo Rueda | Enriched infant formulas |
US20110195144A1 (en) | 2007-11-26 | 2011-08-11 | Nestec S.A. | Age-tailored nutrition system for infants |
CA2730156A1 (en) * | 2008-07-08 | 2010-01-14 | Nestec S.A. | Portion-controlled nutrition system and method using capsules |
EP2554056B1 (en) * | 2008-09-02 | 2019-12-04 | N.V. Nutricia | Nutritional compositions with large diameter lipid globules with a coating comprising phospholipids |
SG172774A1 (en) * | 2009-01-19 | 2011-08-29 | Nestec Sa | Nutritional composition for infants |
EP2452571A1 (en) * | 2010-11-15 | 2012-05-16 | Nestec S.A. | Array of complementary infant/young child nutritional compositions |
CN103404595B (zh) | 2013-07-29 | 2015-04-15 | 北安宜品努卡乳业有限公司 | 一种专为男宝宝设计的婴幼儿配方奶粉 |
-
2014
- 2014-09-01 MX MX2016007634A patent/MX2016007634A/es active IP Right Grant
- 2014-09-01 AU AU2014361224A patent/AU2014361224A1/en not_active Abandoned
- 2014-09-01 US US15/104,027 patent/US20160309768A1/en not_active Abandoned
- 2014-09-01 ES ES14758383T patent/ES2743206T3/es active Active
- 2014-09-01 WO PCT/EP2014/068487 patent/WO2015086170A1/en active Application Filing
- 2014-09-01 RU RU2016128075A patent/RU2678418C1/ru active
- 2014-09-01 EP EP14758383.5A patent/EP3079500B1/en not_active Revoked
- 2014-09-01 CN CN201480066668.4A patent/CN105792677A/zh active Pending
-
2016
- 2016-04-25 PH PH12016500765A patent/PH12016500765A1/en unknown
- 2016-06-10 CL CL2016001454A patent/CL2016001454A1/es unknown
-
2018
- 2018-08-13 AU AU2018217206A patent/AU2018217206A1/en not_active Abandoned
-
2019
- 2019-07-17 US US16/514,301 patent/US11357252B2/en active Active
-
2020
- 2020-07-24 AU AU2020207863A patent/AU2020207863A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080000333A1 (en) * | 2006-06-30 | 2008-01-03 | Nitto Seiko Co., Ltd. | Screw fastening machine |
US20120012175A1 (en) * | 2010-07-19 | 2012-01-19 | Samsung Electronics Co., Ltd. | Solar cell and manufacturing method thereof |
US20130017766A1 (en) * | 2011-07-12 | 2013-01-17 | Iv Technologies Co., Ltd. | Polishing pad, polishing method and polishing system |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019038159A1 (en) * | 2017-08-22 | 2019-02-28 | Nestec S.A. | SEX SPECIFIC SYNTHETIC NUTRIENT COMPOSITIONS AND NUTRIENT SYSTEMS COMPRISING SAME |
CN110996684A (zh) * | 2017-08-22 | 2020-04-10 | 雀巢产品有限公司 | 性别特异性合成营养组合物以及包含其的营养体系产品 |
Also Published As
Publication number | Publication date |
---|---|
CN105792677A (zh) | 2016-07-20 |
AU2020207863A1 (en) | 2020-08-13 |
RU2678418C1 (ru) | 2019-01-28 |
WO2015086170A1 (en) | 2015-06-18 |
MX2016007634A (es) | 2016-10-13 |
PH12016500765A1 (en) | 2016-05-30 |
EP3079500A1 (en) | 2016-10-19 |
US11357252B2 (en) | 2022-06-14 |
AU2018217206A1 (en) | 2018-08-30 |
ES2743206T3 (es) | 2020-02-18 |
US20190335797A1 (en) | 2019-11-07 |
AU2014361224A1 (en) | 2016-05-19 |
CL2016001454A1 (es) | 2017-02-17 |
EP3079500B1 (en) | 2019-06-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11357252B2 (en) | Synthetic milk compositions for optimal growth and development and prevention of obesity in male and female infant and children | |
AU2020201334B2 (en) | Synthetic nutritional compositions especially adapted for male and female infants and young children | |
EP3079499B1 (en) | Synthetic milk compositions comprising polyunsaturated fatty acids (pufas) for promoting the healthy establishment of cognitive function in male and female infant and children | |
EP3073844B1 (en) | Age-tailored nutritional compositions with a varying protein content | |
EP3079497B1 (en) | Synthetic milk compositions comprising n-6 eicosatrienoic acid and polar lipids for infants younger and older than three months for healthy establishment of cognitive function | |
US11980215B2 (en) | Synthetic milk compositions for infants less than three months old and for infants and children more than three months for ensuring optimal growth and preventing obesity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: NESTEC S.A., SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DE CASTRO, CARLOS ANTONIO;DESTAILLATS, FREDERIC;GIUFFRIDA, FRANCESCA;AND OTHERS;SIGNING DATES FROM 20140116 TO 20140207;REEL/FRAME:044009/0501 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
AS | Assignment |
Owner name: SOCIETE DES PRODUITS NESTLE S.A., SWITZERLAND Free format text: MERGER;ASSIGNOR:NESTEC S.A.;REEL/FRAME:049391/0756 Effective date: 20190528 |
|
AS | Assignment |
Owner name: SOCIETE DES PRODUITS NESTLE S.A., SWITZERLAND Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE ENGLISH TRANSLATION TO SHOW THE FULL AND CORRECT NEW NAME IN SECTION 51. PREVIOUSLY RECORDED AT REEL: 049391 FRAME: 0756. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER;ASSIGNOR:NESTEC S.A.;REEL/FRAME:049853/0398 Effective date: 20190528 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: SOCIETE DES PRODUITS NESTLE S.A., SWITZERLAND Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE PATENT NUMBER 16062921 PREVIOUSLY RECORDED ON REEL 049391 FRAME 0756. ASSIGNOR(S) HEREBY CONFIRMS THE PATENT NUMBER SHOULD HAVE BEEN 16062912;ASSIGNOR:NESTEC S.A.;REEL/FRAME:054082/0001 Effective date: 20190528 Owner name: SOCIETE DES PRODUITS NESTLE S.A., SWITZERLAND Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE PATENT NUMBER 16062921 PREVIOUSLY RECORDED ON REEL 049391 FRAME 0756. ASSIGNOR(S) HEREBY CONFIRMS THE PATENT NUMBER SHOULD HAVE BEEN 16062912;ASSIGNOR:NESTEC S.A.;REEL/FRAME:054082/0165 Effective date: 20190528 |